Wird geladen...
Baricitinib: From Rheumatoid Arthritis to COVID‐19
Baricitinib is a JAK1/2 inhibitor that was first approved for treating moderate to severe rheumatoid arthritis (RA) but that later showed considerable efficacy in the control of exaggerated inflammatory responses that occur in a wide range of diseases. There is a growing body of evidence, obtained f...
Gespeichert in:
| Veröffentlicht in: | J Clin Pharmacol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8250677/ https://ncbi.nlm.nih.gov/pubmed/33870531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1874 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|